Background: The prognosis of patients (pts) with recurrent HGG is poor with a median survival of 3 to 6 months. To date, no second line of treatment is recognized as standard. Enhanced angiogenesis has been recognized as a marker of HGG. Antiangiogenetic agents combined to irinotecan (I) have shown major antitumor activity in recurrent HGG. Sunitinib (S) is a selective inhibitor of multiple tyrosine kinases including VEGFR and PDGFR that crosses the blood-brain barrier. We investigated the safety and activity of the combination ..
Phase II study of sunitinib and irinotecan in patients with recurrent high-grade glioma (HGG)
GRISANTI, Salvatore;POLIANI, Pietro Luigi;BUGLIONE DI MONALE E BASTIA, Michela;
2010-01-01
Abstract
Background: The prognosis of patients (pts) with recurrent HGG is poor with a median survival of 3 to 6 months. To date, no second line of treatment is recognized as standard. Enhanced angiogenesis has been recognized as a marker of HGG. Antiangiogenetic agents combined to irinotecan (I) have shown major antitumor activity in recurrent HGG. Sunitinib (S) is a selective inhibitor of multiple tyrosine kinases including VEGFR and PDGFR that crosses the blood-brain barrier. We investigated the safety and activity of the combination ..File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
